MistGo®: Simplicity Meets Usability “It is absolutely brilliant. I really mean it. Incredibly simple to use”, stated one of the patients in our recent study! MistGo® was rated 9.4/10 for ease of use, compared to 6.6/10 for traditional eye drops. The patients aged 39 to 88 embrace MistGo® for its simplicity and ease of use, setting a new benchmark in eye care innovation. Here’s what else they were saying: ”This is very easy to understand”; ”It’s so straightforward, there’s no challenge at all”; “It was just…*puff* and done.” Why it matters: MistGo® combines ease of understanding with effortless functionality, enabling patients to master it on their first try. This empowers users to take control of their eye care confidently and consistently. Could this be the new standard in eye medication? Let us know what you think, or connect with us to learn more! #EYEGO #MISTGO #Ophthalmology #EyeCareInnovation #PatientCenteredDesign
EYE-GO A/S
Medicinsk udstyr
Hørsholm, Capital Region 560 følgere
We shape the future of eye treatment.
Om os
EYE-GO A/S is a Danish MedTech start-up established 2015 based on the work by two designers wanting to develop eye-care technologies that improve the quality of life of people around the world suffering from severe and chronic eye conditions. Problem: Only a fraction of patients achieves the full health outcome of treatment due to imperfections with current eye drop bottles. Users experience difficulties instilling the medication, over-dose due to drop size, side-effects and may abandon prescribed treatment plan leading to poor disease management. This is not just an issue for patients who best case loose quality of life and worst case may end up blind, but also for pharma companies whose drugs don’t have full therapeutic effect, and society ending up with unnecessary high health care spending. Solution: MistGo® is a new generation micro-dosing drug delivery system mitigating the imperfections with current eye-drop bottles. MistGo® makes it simple and comfortable to self-administer the drug correctly with the precisely required amount of drug entering the eye at first go, and helps patients adhere to treatment long-term This cutting-edge eye treatment technology from EYE-GO is suitable for long-term eye care diseases requiring topical ocular treatment and is compatible with preservative-free liquids. Leading ophthalmologists and frontrunning international industry players have already name it an “an ophthalmologic game changer”. Visit our website to learn more, or contact us now on [email protected] (Henrik Nagel, CEO) or [email protected] (Rie Saabye, Director Business Development) to discuss licensing opportunities of an innovative drug delivery system for one or more of your innovative substances.
- Websted
-
http://www.eye-go.com
Eksternt link til EYE-GO A/S
- Branche
- Medicinsk udstyr
- Virksomhedsstørrelse
- 2-10 medarbejdere
- Hovedkvarter
- Hørsholm, Capital Region
- Type
- Privat
- Grundlagt
- 2015
- Specialer
- MedTech, Medico, Medical device, Eye care, Eye treatment, Ophtalmology, Ocular drug administration system, Ophtalmic drug administration system , Chronic eye conditions, Severe eye conditions , Glaucoma, Dry eye disease, Start-up , User experience , Presbyopia, Myopia, Pharma, Combination Product (drug device), Micro dosing og Full effectiveness of eye medication
Produkter
Beliggenheder
-
Primær
Se ruten
Agern Allé 5A
Hørsholm, Capital Region 2970, DK
Medarbejdere hos EYE-GO A/S
Opdateringer
-
Consistency Redefined: MistGo® Delivers Reliable Results Across Patients In the world of eye care, consistency matters. That’s why we’re thrilled to share one of the standout findings from our recently completed study on MistGo®: A very low standard deviation in patient responses! What does it mean? It shows that MistGo® isn’t just effective—it’s reliably effective. Across patients, the results demonstrate consistency in delivering a positive experience. This underscores our commitment to a patient-first design that works for everyone, every time. At EYE-GO, we believe that predictable, high-quality care is key to transforming eye health. MistGo® is proving to be a solution clinicians and patients alike can depend on. Join the conversation! If you’re interested in improving patient outcomes or partnering with us to advance eye care innovations, let’s connect. #EYEGO #MISTGO #Ophthalmology #ConsistencyInCare #PatientCenteredDesign
-
-
Study Results: MistGo® Sets a New Standard in Eye Care The results are in! EYE-GO’s recent study involving 22 patients with glaucoma or high eye pressure over 14 days highlights the transformative impact of MistGo® on eye medication delivery. Here’s what we learned: Key findings: 1. Exceptional User-Friendliness: Patients rated MistGo® 9.4/10 for ease of use, compared to 6.6/10 for traditional eye drops. “It was just…puff and done. Incredibly simple to use” 2. Superior Comfort: MistGo® achieved a 9.5/10 comfort rating, surpassing traditional eye drops at 7.2/10. “There was no discomfort at all. Much more comfortable to eye drops”. 3. Minimal Waste, Maximum Precision: Patients reported being significantly less bothered by excess liquid, with MistGo® scoring 9.9/10 vs 5.8/10 for traditional eye drops. 4. Overwhelming Preference: 20 of 22 participants indicated a preference for MistGo® over traditional eye drops. “This will help a lot of people! When will it be on the market?” What’s next? EYE-GO is eager to bring these results to life. If you’re an investor or ophthalmology player passionate about transforming patient outcomes, let’s connect! #EYEGO #MISTGO #Ophthalmology #StudyResults
-
-
EYE-GO at OIS: Shaping the Future of Eye Care Last week at OIS, EYE-GO’s CEO Henrik Nagel presented groundbreaking results from our latest study involving glaucoma patients. We’re proud to share how our innovation can make tangible impacts on patient care. Engaging with fellow leaders and visionaries in ophthalmology was inspiring and motivating as we continue to push the boundaries of eye health solutions. Let’s keep innovating and transforming patient outcomes together! #EYEGO #MISTGO #Ophthalmology #Innovation #OIS
-
-
Transforming Eye Care with MistGo: A Patient-Centered Revolution Traditional eye drops often pose challenges with dosing inaccuracies, discomfort, and usability issues. At EYE-GO, we’re addressing these concerns head-on with MistGo®, a solution designed with patients at its core. Our goal is to redefine the standard of eye care by making treatments effective, more comfortable, and user-friendly. We are concluding a study in which glaucoma patients tested MistGo® over 14 days—and the results speak for themselves! Stay tuned as we share insights from our recently completed study in the coming weeks. #EYEGO #MISTGO #Ophthalmology #PatientCentered
-
-
We are excited to share updates about MistGo® at OIS XIV on November 22-23 in San Diego.
𝗘𝘅𝗰𝗶𝘁𝗶𝗻𝗴 𝗔𝗻𝗻𝗼𝘂𝗻𝗰𝗲𝗺𝗲𝗻𝘁! The OIS XIV presenting company lineup is here, featuring industry leaders and game-changing innovations you won’t want to miss! 𝗦𝗲𝗰𝘂𝗿𝗲 𝘆𝗼𝘂𝗿 𝘀𝗽𝗼𝘁 𝗻𝗼𝘄 𝗮𝗻𝗱 𝗯𝗲 𝗽𝗮𝗿𝘁 𝗼𝗳 𝘁𝗵𝗲 𝗶𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻! https://lnkd.in/gheE53xh Adverum Biotechnologies, AesculaTech, AiViva Biopharma, Inc., Ascidian Therapeutics, Aura Biosciences, Aurion Biotech, BioTissue, Clearside Biomedical, Inc., Emmecell, Everads Therapy Ltd, Eyedaptic, Eyegenex, EYE-GO A/S, FELIQS, GlaucoT, Horizon Surgical Systems, Kejako, Kiora Pharmaceuticals, Inc., LENZ Therapeutics, LEP Biomedical, Lubris BioPharma, LumiThera, Inc., MediPrint Ophthalmics, Nanodropper, Inc., Novaliq GmbH, NovaSight, Ocudyne Inc, Ocular Therapeutix, Inc., Oculis, ONL Therapeutics, Opthea, Outlook Therapeutics, Inc., Ray Therapeutics, Inc., REGENXBIO, Seinda Pharmaceutical Corporation, Stuart Therapeutics, Uneedle, Valitor, VIAN Therapeutics, Viridian Therapeutics, Inc. #OIS #OISXIV #Ophthalmology #Innovation #PresentingCompanies
-
-
EYE-GO's Collaboration with DTI Featured on GTS’ Website GTS ' website features EYE-GO's development journey and collaboration with the Danish Technological Institute (DTI) as a case study. Morten Jacobsen, EYE-GO’s senior project manager, was interviewed by GTS, an industry organization for approved technological service organizations in Denmark. DTI’s expertise played a vital role in product testing to guarantee the sterility of MistGo®. EYE-GO's MistGo® micro-dosing device simplifies the application of eye medication, ensuring accurate dosage and reducing waste. Check out the complete case study below (article in Danish). #MedTech #Ophthalmology #Sterility #MistGo #EYEGO #DTI #GTS
IVÆRKSÆTTERVIRKSOMHED ER KLAR MED NY DEVICE TIL ØJENDRÅBER 🤩 Har du nogensinde kæmpet med øjendråber? Det er du ikke alene om! Ny device kaldet MistGo® gør det langt nemmere at bruge øjenmedicin 🙏 Iværksættervirksomheden EYE-GO, står bag det nye produkt. Ifølge senior project manager, Morten Jacobsen, har der været meget lidt udvikling af de beholdere, der bruges til øjenmedicin: "Det skyldes, at medicinalfirmaerne primært har fokus på selve medicinen og ikke det rundt om," forklarer han. Det har EYE-GO A/S sat sig for at ændre på. Derfor har de udviklet MistGo® – et kombinationsprodukt, der integrerer device og medicin. Udviklingen af produktet har tager omkring 10 år og undervejs har det været gennemført test bl.a. i samarbejde med Teknologisk Institut. ”Vi havde brug for et sted, der var fleksibelt og med mulighed for at tilpasse undervejs. Den tilgang fandt vi hos mikrobiologisk laboratorium hos Teknologisk Institut. Vi sætter stor pris på deres tilgang til samarbejdet. Det handler ikke blot om at booke to timer til en test. Vi bruger også meget tid på at tale om, hvordan vi skal gennemføre testene, så vi får præcis det ud af dem, som vi ønsker, og her har vi stor glæde af deres erfaring”, fortæller Morten Jacobsen. Læs hele casen 👇 https://lnkd.in/ecNsM7Hw
-
EYE-GO Ready to Launch First Study Investigating MistGo® with Glaucoma Patients Exciting news! EYE-GO is ready to start our first study evaluating the use of MistGo® with glaucoma patients. During this study, traditional eyedropper bottles will be replaced with MistGo®, offering a promising alternative for drug delivery. MistGo® simplifies and improves the administration of eye medication, ensuring patients receive the correct dose comfortably and efficiently. More updates to come as we take this exciting step towards transforming eye care. #MedTech #Innovation #EyeCare #Glaucoma #MistGo #EYEGO #PatientCare
-
-
Meet EYE-GO in Barcelona in September! EYE-GO’s CEO Henrik Nagel will be present at Ophthalmology Futures Forums 2024. Feel free to reach out if you are curious about EYE-GO and our drug delivery system MistGo®. #EYEGO #OphthalmologyFuturesForums #DrugDelivery
-
-
EYE-GO Receives Third Grant from Innovation Fund Denmark's Innobooster Program We are pleased to announce that EYE-GO has once again been awarded a grant from Innovation Fund Denmark's Innobooster program, supporting the development of our innovative delivery device, MistGo®. The grant will allow us to further enhance MistGo's capabilities, ensuring precise dosing with unmatched accuracy and reliability for our users. Receiving this funding reflects our dedication to innovation and underscores MistGo's potential to transform the delivery device industry. We are thankful for Innovation Fund Denmark's continued support and recognition of our efforts to push the boundaries of technology. We look forward to sharing more updates as we progress towards bringing MistGo® to market. #EYE-GO #Ophthalmology #SoftFunding #Innovation
-